214 related articles for article (PubMed ID: 10090423)
1. Expanded activity and utility of the new fluoroquinolones: a review.
Blondeau JM
Clin Ther; 1999 Jan; 21(1):3-40; discussion 1-2. PubMed ID: 10090423
[TBL] [Abstract][Full Text] [Related]
2. A critical review of the fluoroquinolones: focus on respiratory infections.
Zhanel GG; Ennis K; Vercaigne L; Walkty A; Gin AS; Embil J; Smith H; Hoban DJ
Drugs; 2002; 62(1):13-59. PubMed ID: 11790155
[TBL] [Abstract][Full Text] [Related]
3. Levofloxacin and sparfloxacin: new quinolone antibiotics.
Martin SJ; Meyer JM; Chuck SK; Jung R; Messick CR; Pendland SL
Ann Pharmacother; 1998 Mar; 32(3):320-36. PubMed ID: 9533064
[TBL] [Abstract][Full Text] [Related]
4. Comparative in vitro activity of gatifloxacin, grepafloxacin, levofloxacin, moxifloxacin and trovafloxacin against 4151 Gram-negative and Gram-positive organisms.
Blondeau JM; Laskowski R; Bjarnason J; Stewart C
Int J Antimicrob Agents; 2000 Feb; 14(1):45-50. PubMed ID: 10717500
[TBL] [Abstract][Full Text] [Related]
5. In vitro antibacterial activity and pharmacodynamics of new quinolones.
Dalhoff A; Schmitz FJ
Eur J Clin Microbiol Infect Dis; 2003 Apr; 22(4):203-21. PubMed ID: 12687416
[TBL] [Abstract][Full Text] [Related]
6. Quinolone activity against anaerobes.
Appelbaum PC
Drugs; 1999; 58 Suppl 2():60-4. PubMed ID: 10553708
[TBL] [Abstract][Full Text] [Related]
7. Possible role for the new fluoroquinolones (levofloxacin, grepafloxacin, trovafloxacin, clinafloxacin, sparfloxacin, and DU-6859a) in the treatment of anaerobic infections: review of current information on efficacy and safety.
Goldstein EJ
Clin Infect Dis; 1996 Dec; 23 Suppl 1():S25-30. PubMed ID: 8953103
[TBL] [Abstract][Full Text] [Related]
8. [The history of the development and changes of quinolone antibacterial agents].
Takahashi H; Hayakawa I; Akimoto T
Yakushigaku Zasshi; 2003; 38(2):161-79. PubMed ID: 15143768
[TBL] [Abstract][Full Text] [Related]
9. In-vitro activity of clinafloxacin, trovafloxacin, and ciprofloxacin.
Cohen MA; Huband MD; Gage JW; Yoder SL; Roland GE; Gracheck SJ
J Antimicrob Chemother; 1997 Aug; 40(2):205-11. PubMed ID: 9301985
[TBL] [Abstract][Full Text] [Related]
10. The new fluoroquinolones: A critical review.
Zhanel GG; Walkty A; Vercaigne L; Karlowsky JA; Embil J; Gin AS; Hoban DJ
Can J Infect Dis; 1999 May; 10(3):207-38. PubMed ID: 22346384
[TBL] [Abstract][Full Text] [Related]
11. Gatifloxacin: a review of its use in the management of bacterial infections.
Perry CM; Ormrod D; Hurst M; Onrust SV
Drugs; 2002; 62(1):169-207. PubMed ID: 11790160
[TBL] [Abstract][Full Text] [Related]
12. Levofloxacin: a review of its use in the treatment of bacterial infections in the United States.
Croom KF; Goa KL
Drugs; 2003; 63(24):2769-802. PubMed ID: 14664657
[TBL] [Abstract][Full Text] [Related]
13. A review of the comparative in-vitro activities of 12 antimicrobial agents, with a focus on five new respiratory quinolones'.
Blondeau JM
J Antimicrob Chemother; 1999 May; 43 Suppl B():1-11. PubMed ID: 10382869
[TBL] [Abstract][Full Text] [Related]
14. Levofloxacin and trovafloxacin: the next generation of fluoroquinolones?
Ernst ME; Ernst EJ; Klepser ME
Am J Health Syst Pharm; 1997 Nov; 54(22):2569-84. PubMed ID: 9397218
[TBL] [Abstract][Full Text] [Related]
15. Antibacterial activities of grepafloxacin, ciprofloxacin, ofloxacin and fleroxacin.
Barry AL; Fuchs PC
J Chemother; 1997 Feb; 9(1):9-16. PubMed ID: 9106012
[TBL] [Abstract][Full Text] [Related]
16. Evidence of different profiles of side effects and drug-drug interactions among the quinolones--the pharmacokinetic standpoint.
Lode H
Chemotherapy; 2001; 47 Suppl 3():24-31; discussion 44-8. PubMed ID: 11549786
[TBL] [Abstract][Full Text] [Related]
17. Review of third-and fourth-generation fluoroquinolones in ophthalmology: in-vitro and in-vivo efficacy.
Scoper SV
Adv Ther; 2008 Oct; 25(10):979-94. PubMed ID: 18836691
[TBL] [Abstract][Full Text] [Related]
18. A Review of New Fluoroquinolones : Focus on their Use in Respiratory Tract Infections.
Zhanel GG; Fontaine S; Adam H; Schurek K; Mayer M; Noreddin AM; Gin AS; Rubinstein E; Hoban DJ
Treat Respir Med; 2006; 5(6):437-65. PubMed ID: 17154673
[TBL] [Abstract][Full Text] [Related]
19. In vitro activity of newer fluoroquinolones for respiratory tract infections and emerging patterns of antimicrobial resistance: data from the SENTRY antimicrobial surveillance program.
Jones RN; Pfaller MA
Clin Infect Dis; 2000 Aug; 31 Suppl 2():S16-23. PubMed ID: 10984323
[TBL] [Abstract][Full Text] [Related]
20. In-vitro activities of ciprofloxacin, levofloxacin, lomefloxacin, ofloxacin, pefloxacin, sparfloxacin and trovafloxacin against gram-positive and gram-negative pathogens from respiratory tract infections.
Hoogkamp-Korstanje JA
J Antimicrob Chemother; 1997 Sep; 40(3):427-31. PubMed ID: 9338498
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
